Mirum Pharmaceuticals Inc... (MIRM)
53.20
1.03 (1.97%)
At close: Feb 20, 2025, 3:59 PM
53.16
-0.08%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 49.59 |
| Market Cap | 2.55B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.08 |
| PE Ratio (ttm) | -25.58 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 54.81 |
| Volume | 434,184 |
| Avg. Volume (20D) | 447,803 |
| Open | 52.17 |
| Previous Close | 52.17 |
| Day's Range | 51.87 - 53.49 |
| 52-Week Range | 23.14 - 53.76 |
| Beta | undefined |
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment o...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 18, 2019
Employees 311
Stock Exchange NASDAQ
Ticker Symbol MIRM
Website https://www.mirumpharma.com
Analyst Forecast
According to 10 analyst ratings, the average rating for MIRM stock is "Buy." The 12-month stock price forecast is $63, which is an increase of 18.42% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Mirum Pharmaceuticals Inc. is scheduled to release its earnings on Feb 26, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
8 months ago
+27.31%
Mirum Pharmaceuticals shares are trading higher af...
Unlock content with
Pro Subscription
11 months ago
+1.44%
Mirum Pharmaceuticals shares are trading higher after the company announced that the FDA approved LIVMARLI oral solution for the treatment of cholestatic pruritus in patients five years of age and older with progressive familial intrahepatic cholestasis. Also, HC Wainwright maintained a Buy rating on the stock and raised its price target from $45 to $58.
